Per the fiscal second-quarter earnings call, the company continues to remain aggressive when it comes to cost control measures. We anticipate these to get reflected in the fiscal third-quarter results.
Moreover, the company has been committed toward improving efficiencies across its Medical segment by refining commercial, operational and data capabilities. In the fiscal third quarter, revenues at this segment are likely to reflect increase in sales from personal protective equipment (PPE) and increase in volumes in its lab business.
Notably, the segment manufactures products such as single-use surgical drapes, gowns and apparel, exam and surgical gloves, which may have favored sales in the to-be-reported quarter. Consequently, this trend is likely to have sustained in the to-be-reported quarter.Īlso, Cardinal Health’s Medical unit may have contributed significantly to the overall fiscal third-quarter performance. The upside can be attributed to growth in sales from Pharmaceutical Distribution and Specialty Solutions customers. In the fiscal second quarter, pharmaceutical revenues rose 4.3% to $37.24 billion on a year-over-year basis. price-eps-surprise | Cardinal Health, Inc. Price and EPS SurpriseĬardinal Health, Inc. In fact, higher contribution from key growth areas - Specialty and Connected Care - and sustained dynamics within its generics program are likely to have favored the segment’s performance in the to-be-reported quarter. This might get reflected in the segment’s results in the to-be-reported quarter. Elective procedures and physician office visits are expected to recover to pre-COVID 19 levels exiting fiscal 2021, with a more substantial impact in the first half of the year. Factors to NoteĬardinal Health’s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States. The same for revenues stands at $39.99 billion, suggesting growth of 2.1% from the year-ago reported figure. Q3 Estimatesįor the fiscal third quarter, the Zacks Consensus Estimate for earnings is pegged at $1.57 per share, indicating a decline 3.1% from the prior-year quarter. It beat estimates in each of the trailing four quarters, the average surprise being 20%. In the last reported quarter, the company delivered an earnings surprise of 20%. CAH is scheduled to report third-quarter fiscal 2021 results on May 6, before the opening bell.
0 kommentar(er)
